
    
      This is a randomized (to each eye, within patient), double-blinded, placebo-controlled study
      of the efficacy of Processed Amniotic Fluid (pAF) in patients with hematologic malignancies
      who have undergone Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) and are
      diagnosed with Chronic Graft Verses Host Disease of the eye.
    
  